Check-Mate 141 Results: Nivolumab Improved OS in Patients With Recurrent or Metastatic Head and Neck CancerApril 18, 2018
Not all patients who received nivolumab, however, had improved PFS.
At the time of final analysis, 192 of 302 patients had died.
Doses of at least 60 mg yielded tumor reductions of 2% to 70% among 25 of the 30 evaluated patients.
One instance of grade 3 alanine aminotransferase elevation and 5 instances of reversible immune-related adverse events were observed.
Improvement in RFS was seen regardless of PD-L1 status.
At surgery, blood samples were taken from 163 patients; whole genome sequencing and whole exome signaling were performed on detected CTCs.
Researchers infected various tumor cell lines with anti-rotavirus vaccines confirmed to be PRR agonists.
Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.
Antigen-specific T cells increased in frequency in vaccinated mice.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Post-Surgery Accelerated Partial Breast Irradiation vs Whole-Breast Irradiation: QoL Outcomes
- Widening the Use of Preventive Therapies Against Breast Cancer
- Lenalidomide: Feasible for Patients With Relapsed, Refractory MCL
- Bloodroot and Cancer
- Perioperative Gabapentin May Improve Pain Management in Head and Neck Cancer